Eurosurv. Vaccine effectiveness against infection with the Delta (B.1.617.2) variant, Norway, April to August 2021

[tetano]

• Elina Seppälä[SUP]1,4,*[/SUP] , Lamprini Veneti[SUP]2,*[/SUP] , Jostein Starrfelt [SUP]2[/SUP] , Anders Skyrud Danielsen[SUP]2[/SUP] , Karoline Bragstad[SUP]3[/SUP] , Olav Hungnes[SUP]3[/SUP] , Arne Michael Taxt[SUP]1[/SUP] , Sara Viksmoen Watle[SUP]1[/SUP] , Hinta Meijerink[SUP]1[/SUP]

Some variants of SARS-CoV-2 are associated with increased transmissibility, increased disease severity or decreased vaccine effectiveness (VE). In this population-based cohort study (n = 4,204,859), the Delta variant was identified in 5,430 (0.13%) individuals, of whom 84 were admitted to hospital. VE against laboratory confirmed infection with the Delta variant was 22.4% among partly vaccinated (95% confidence interval (CI): 17.0−27.4) and 64.6% (95% CI: 60.6−68.2) among fully vaccinated individuals, compared with 54.5% (95% CI: 50.4−58.3) and 84.4% (95%CI: 81.8−86.5) against the Alpha variant.

full article


https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.35.2100793#html_fulltext